Global Myeloproliferative Disorder Drugs Market Research Report 2022 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Myeloproliferative Disorder Drugs Market Analysis by Therapeutic Area (Ph+ Chronic myelogenous leukaemia (CML), Ph- Myeloproliferative Neoplasms (MPNs)) and by Region – Forecast to 2026” report has been added to ResearchAndMarkets.com’s offering.

The global myeloproliferative disorder drugs market is estimated to be USD 8,741.4 million in 2021 and is expected to witness a CAGR of 3.81% to 2029

Growing research and development activities in the fields of myeloproliferative disorder drugs and technological advancements for improving patient results are driving the global market. However, the side effects of the novel drugs due to inadequate research and stringency of regulatory procedures related to production and use of these drugs are hindering the market growth.

By Therapeutic Area

Based on therapeutic area, the market is segmented into Ph+ Chronic myelogenous leukaemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs).

In 2021, the Ph- Myeloproliferative Neoplasms (MPNs) segment accounted for the significant share owing to increasing number of patients and technological advancements. This segment is anticipated to grow at a significant CAGR during the forecast period owing to continuous investments by the government.

Regional Insights

North America dominated the global market in 2021 and is expected to maintain its dominance during the forecast period. Multiple product launches by major players, growing adoption of new therapeutics, and presence of a large target population are the major drivers for the growth in this region.

Asia Pacific segment is estimated to grow at a fastest CAGR during the forecast period owing to the presence of a large population, rising prevalence of myeloproliferative disorders, rising awareness, and developing healthcare infrastructure in this region.

Competitor Insights

Investment in R&D, novel product launches, investment in R&D and strategic collaborations & M&A are some of the major strategies adopted by the leading players operating in the industry.

Companies Mentioned

• Novartis AG (Switzerland)
• Bristol-Myers Squibb Company (U.S.)
• Pfizer Inc. (U.S.)
• Takeda Pharmaceutical Company Ltd. (Japan) Incyte Corporation. (U.S.)
• Teva Pharmaceutical Industries Ltd (Israel).

Myeloproliferative Disorder Drugs Market, By Type (Revenue, 2021-2029, USD Million)

• Ph- Myeloproliferative Neoplasms (MPNs)
• Polycythaemia Vera (PV)
• Myelofibrosis (MF)
• Essential thrombocythemia (ET)
• Ph+ Chronic myelogenous leukaemia (CML)

Myeloproliferative Disorder Drugs Market, By Region (Revenue, 2021-2029, USD Million)

North America

• U.S.
• Canada

Europe

• Germany
• France
• UK
• Spain
• Italy
• Russia
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Rest of APAC

Latin America

• Brazil
• Mexico
• Argentina
• Rest of LATAM

Middle East & Africa

• South Africa
• Saudi Arabia
• Rest of MEA

For more information about this report visit https://www.researchandmarkets.com/r/kmsnbs

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900